Page last updated: 2024-11-04

sulforaphane and Pervasive Child Development Disorders

sulforaphane has been researched along with Pervasive Child Development Disorders in 1 studies

sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Singh, K1
Connors, SL1
Macklin, EA1
Smith, KD1
Fahey, JW1
Talalay, P1
Zimmerman, AW1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Sulforaphane in Autism: A Treatment Trial to Confirm Phenotypic Improvement With Sulforaphane Treatment in a New Jersey (NJ) Population of Individuals With Autism[NCT02677051]Phase 248 participants (Actual)Interventional2016-02-29Active, not recruiting
Decreasing Risk of Psychosis by Sulforaphane: Study Protocol for a Randomized, Double-blind, Placebo-controlled, Clinical Multicenter Trial (DROPS Trial)[NCT03932136]Phase 3300 participants (Anticipated)Interventional2019-07-14Recruiting
Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure[NCT03730649]Early Phase 1120 participants (Anticipated)Interventional2019-10-09Recruiting
Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD)[NCT02561481]Phase 1/Phase 260 participants (Actual)Interventional2015-12-31Completed
A 12-weeks, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Related Mechanism of Sulforaphane in Treatment of Autism Spectrum Disorder[NCT02879110]110 participants (Actual)Interventional2016-08-31Completed
A Pilot Project to Validate Digital Bio-markers as a Tool to Measure Improvement in Core Symptoms of Autism During Sulforaphane Treatment.[NCT04805957]10 participants (Anticipated)Interventional2022-07-07Enrolling by invitation
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Ohio Autism Clinical Impressions Scale - Improvement (OACIS-I) Average Score From Baseline

The Ohio Autism Clinical Impressions Scale-Severity (OACIS-S) rates severity of symptoms in 10 categories: general level of autism, social interaction, aberrant and repetitive behavior, verbal and nonverbal communication, hyperactivity, anxiety, sensory sensitivities and restricted and narrow interests. Each category is rated from 1 (normal) to 7 (most severe). The OACIS-S was a reference at follow up visits when the OACIS-Improvement was compared to the OACIS-S, from 1 to 7: 4 was no change; 3 to 1 minimal to marked improvement and 5 to 7 minimal to marked worsening. The numerical score of the OACIS-S is independent and unrelated quantitatively to the OACIS-I. For analysis, the OACIS-I general score and subscale values were recoded, in which 4 (no change) was recoded as 0; 3 to 1 were recoded as +1 to +3 to denote improvement, and 5 to 7 were recoded as -1 to -3 for worsening. (NCT02561481)
Timeframe: 7 weeks, 15 weeks, 22 weeks, 30 weeks, 36 weeks

,
Interventionscore on a scale (Mean)
7 weeks15 weeks22 weeks30 weeks36 weeks
Placebo0.280.330.590.690.29
Sulforaphane0.280.280.470.470.29

Change in Total Aberrant Behavior Checklist Score From Baseline

Aberrant Behavior Checklist (ABC) is a 58 item scale that primarily evaluates how aberrant or abnormal a patient's daily behaviors are. The items evaluate behaviors as they pertain to irritability, lethargy/social withdrawal, stereotypic behavior, hyperactivity/noncompliance, and inappropriate speech. Each item is scored on a scale of 0 to 3, with 0 being better outcome and 3 being worse outcome. The score from each item is added up to calculate a total score. This outcome describes change in total ABC score from baseline at each follow up visit. The scores from all items are added to calculate a total score (0 to 174). This outcome describes change in total ABC score from baseline at each follow up visit. (NCT02561481)
Timeframe: 7 weeks, 15 weeks, 22 weeks, 30 weeks, 36 weeks

,
Interventionscore on a scale (Mean)
7 weeks15 weeks22 weeks30 weeks36 weeks
Placebo-16.23-11.68-22.4-10.29-7.8
Sulforaphane-6-22.6-36.33-22.81.14

Change in Total SRS-2 Score From Baseline

The Social Responsiveness Scale-2 (SRS-2) is a 65-item scale that measures total scores as well as subscales: four social behaviors (awareness, cognition, communication and motivation) and autistic mannerisms. Each item is rated from 1 to 4 (not true to almost always true) on worksheets that are blinded to the rater with respect to values. Total and subscale scores are calculated as raw scores and can be converted to T-scores. Raw scores (range 0-180) are reported here (unadjusted for general population, since all children had ASD). Higher or lower values at follow up visits compared to baseline indicated worsening or improvement, respectively. (NCT02561481)
Timeframe: 7 weeks, 15 weeks, 22 weeks, 30 weeks, 36 weeks

,
Interventionscore on a scale (Mean)
7 weeks15 weeks22 weeks30 weeks36 weeks
Placebo-8.06-7.92-13.67-18.59-19.59
Sulforaphane1.14-16.86-14.61-19.830.80

Comparison of Free Reduced Glutathione (GSH), Total GSH, Oxidized Glutathione (GSSG) at Week 0 and 15

F-statistic calculated by comparison of Free Reduced GSH, Total GSH and oxidized Glutathione (GSSG) of Week 15 to Week 0. (NCT02561481)
Timeframe: Week 0 and Week 15

,
InterventionF-statistic (Number)
Free Reduced GSHTotal GSHGSSG
Placebo0.110.080.46
Sulforaphane1.510.001.97

Cox-2

Cox-2 (cyclooxygenase-2): a nuclear factor-kappa B - regulated inflammatory biomarker. Total cellular RNA was isolated from peripheral blood mononuclear cells (PBMCs) and complementary DNAs (cDNA) were synthesized. Quantitative real-time PCR analysis was performed using the Applied Biosystems QuantStudio™ 3 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Relative mRNA expression was normalized to GAPDH. Gene expression was calculated using the comparative 2-ΔΔCT method. (NCT02561481)
Timeframe: Week 0, Week 15, Week 30

,
Interventionlog fold change (Mean)
Week 0Week 15Week 30
Placebo-0.200.16-0.17
Sulforaphane0.14-0.07-0.46

Dithiocarbamate Plasma Concentration Detected by Cyclocondensation at Each Visit

Sulforaphane (and other isothiocyanates, ITC) are conjugated by glutathione (GSH) which then undergoes further enzymatic modifications to give rise sequentially to the cysteinylglycine-, cysteine- and N-acetylcysteine-ITC conjugates, all of which are dithiocarbamates (DTC) and are detected in the cyclocondensation reaction-HPLC assay. (NCT02561481)
Timeframe: Week 0, Week 7, Week 15, Week 22, Week 30, Week 36

,
Interventionnmol DTC (Dithiocarbamates)/ml (Mean)
Week 0Week 7Week 15Week 22Week 30Week 36
Placebo0.0060.0030.0050.2050.2140.008
Sulforaphane0.0070.2990.3290.2480.1650.015

Free GSH:GSSG and Total GSH:GSSG Ratios at Week 15

Ratios of free GSH:GSSG and total GSH:GSSG were calculated by obtaining ratios of f-statistic scores from baseline to week 15 between free reduced GSH and GSSG and between total GSH and GSSG. (NCT02561481)
Timeframe: Week 15

,
InterventionF-statistic (Number)
Free GSH:GSSGTotal GSH:GSSG
Placebo0.870.03
Sulforaphane12.725.16

HO-1 (Heme Oxygenase 1)

HO-1 (heme oxygenase 1): an essential and Nrf2-dependent enzyme in heme catabolism. Total cellular RNA was isolated from peripheral blood mononuclear cells (PBMCs) and complementary DNAs (cDNA) were synthesized. Quantitative real-time PCR analysis was performed using the Applied Biosystems QuantStudio™ 3 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Relative mRNA expression was normalized to GAPDH. Gene expression was calculated using the comparative 2-ΔΔCT method. (NCT02561481)
Timeframe: Week 0, Week 15, Week 30

,
Interventionlog fold change (Mean)
Week 0Week 15Week 30
Placebo0.270.550.30
Sulforaphane0.100.740.74

HSP27

HSP27 (Heat shock protein 27) was examined because it is upregulated by SF in vitro. Total cellular RNA was isolated from peripheral blood mononuclear cells (PBMCs) and complementary DNAs (cDNA) were synthesized. Quantitative real-time PCR analysis was performed using the Applied Biosystems QuantStudio™ 3 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Relative mRNA expression was normalized to GAPDH. Gene expression was calculated using the comparative 2-ΔΔCT method. (NCT02561481)
Timeframe: Week 0, Week 15, Week 30.

,
Interventionlog fold change (Mean)
Week 0Week 15Week 30
Placebo-0.13-0.83-0.58
Sulforaphane0.210.21-0.47

HSP70

HSP70 (Heat shock protein 70) was examined because it is upregulated by SF in vitro. Total cellular RNA was isolated from peripheral blood mononuclear cells (PBMCs) and complementary DNAs (cDNA) were synthesized. Quantitative real-time PCR analysis was performed using the Applied Biosystems QuantStudio™ 3 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Relative mRNA expression was normalized to GAPDH. Gene expression was calculated using the comparative 2-ΔΔCT method. (NCT02561481)
Timeframe: Week 0, Week 15, Week 30

,
Interventionlog fold change (Mean)
Week 0Week 15Week 30
Placebo0.991.141.20
Sulforaphane1.111.331.23

IL-1β

IL-1β: Interleukin-1 beta cytokine gene expression, a nuclear factor-kappa B - regulated inflammatory biomarker. Total cellular RNA was isolated from peripheral blood mononuclear cells (PBMCs) and complementary DNAs (cDNA) were synthesized. Quantitative real-time PCR analysis was performed using the Applied Biosystems QuantStudio™ 3 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Relative mRNA expression was normalized to GAPDH. Gene expression was calculated using the comparative 2-ΔΔCT method. (NCT02561481)
Timeframe: Week 0, Week 15, Week 30

,
Interventionlog fold change (Mean)
Week 0Week 15Week 30
Placebo1.141.471.59
Sulforaphane0.901.451.50

IL-6

IL-6 (interleukin 6) cytokine gene expression, a nuclear factor-kappa B - regulated inflammatory biomarker. Total cellular RNA was isolated from peripheral blood mononuclear cells (PBMCs) and complementary DNAs (cDNA) were synthesized. Quantitative real-time PCR analysis was performed using the Applied Biosystems QuantStudio™ 3 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Relative mRNA expression was normalized to GAPDH. Gene expression was calculated using the comparative 2-ΔΔCT method. (NCT02561481)
Timeframe: Week 0, Week 15, Week 30

,
Interventionlog fold change (Mean)
Week 0Week 15Week 30
Placebo1.821.872.08
Sulforaphane1.762.051.99

NQO1: NAD(P)H:Quinone Oxidoreductase-1

Cytoprotective enzyme regulated by nuclear factor erythroid 2-related factor 2 (Nrf2), the master regulator of cellular redox homeostasis and an inhibitor of a key pro-inflammatory pathway, of which both functions are critical factors in the neuropathology of ASD. Total cellular RNA was isolated from peripheral blood mononuclear cells (PBMCs) and complementary DNAs (cDNA) were synthesized. Quantitative real-time PCR analysis was performed using the Applied Biosystems QuantStudio™ 3 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Relative mRNA expression was normalized to GAPDH. Gene expression was calculated using the comparative 2-ΔΔCT method. (NCT02561481)
Timeframe: Week 0, Week 15, Week 30

,
Interventionlog fold change (Mean)
Week 0 (baseline)Week 15Week 30
Placebo2.252.142.13
Sulforaphane2.232.192.15

OACIS-I Response Rate on Aberrant Behaviors Subscale

See above in the primary outcome measure for a description of OACIS-I scale. This section describes the change from baseline of the OACIS-I subdomain of aberrant behaviors. This subdomain has a range of 1 to 7 - 1 is extremely improved from baseline, 7 is extremely worse from baseline, and 4 is no change. For analysis, the OACIS-I general score and subscale values were recoded, in which 4 (no change) was recoded as 0; 3 to 1 were recoded as +1 to +3 to denote improvement, and 5 to 7 were recoded as -1 to -3 for worsening. (NCT02561481)
Timeframe: 7 weeks, 15 weeks, 22 weeks, 30 weeks, 36 weeks

,
Interventionscore on a scale (Mean)
7 weeks15 weeks22 weeks30 weeks36 weeks
Placebo0.280.330.530.590.14
Sulforaphane0.060.220.590.630.14

OACIS-I Response Rate on Social Communication Subscale

See above in the primary outcome measure for a description of OACIS-I scale. This section describes the change from baseline of the OACIS-I subdomain of social communication. This subdomain has a range of 1 to 7 - 1 is extremely improved from baseline, 7 is extremely worse from baseline, and 4 is no change. For analysis, the OACIS-I general score and subscale values were recoded, in which 4 (no change) was recoded as 0; 3 to 1 were recoded as +1 to +3 to denote improvement, and 5 to 7 were recoded as -1 to -3 for worsening. (NCT02561481)
Timeframe: 7 weeks, 15 weeks, 22 weeks, 30 weeks, 36 weeks

,
Interventionscore on a scale (Mean)
7 weeks15 weeks22 weeks30 weeks36 weeks
Placebo0.560.561.351.250.61
Sulforaphane0.330.440.650.940.32

TNF-α

TNF-α (Tumor necrosis factor alpha), a cytokine as inflammatory biomarker. Total cellular RNA was isolated from peripheral blood mononuclear cells (PBMCs) and complementary DNAs (cDNA) were synthesized. Quantitative real-time PCR analysis was performed using the Applied Biosystems QuantStudio™ 3 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Relative mRNA expression was normalized to GAPDH. Gene expression was calculated using the comparative 2-ΔΔCT method. (NCT02561481)
Timeframe: Week 0, Week 15, Week 30

,
Interventionlog fold change (Mean)
Week 0Week 15Week 30
Placebo0.911.081.10
Sulforaphane0.700.981.17

xCT

xCT (SLC7A11): Cystine/glutamate antiporter encoded by the SLC7A11 gene.Total cellular RNA was isolated from peripheral blood mononuclear cells (PBMCs) and complementary DNAs (cDNA) were synthesized. Quantitative real-time PCR analysis was performed using the Applied Biosystems QuantStudio™ 3 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Relative mRNA expression was normalized to GAPDH. Gene expression was calculated using the comparative 2-ΔΔCT method. (NCT02561481)
Timeframe: Week 0, Week 15, Week 30

,
Interventionlog fold change (Mean)
Week 0Week 15Week 30
Placebo0.400.300.27
Sulforaphane0.240.250.24

Trials

1 trial available for sulforaphane and Pervasive Child Development Disorders

ArticleYear
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014
Sulforaphane treatment of autism spectrum disorder (ASD).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Oct-28, Volume: 111, Issue:43

    Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos;

2014